Trials / Completed
CompletedNCT03087162
Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori
Once Daily Dose Dexlansoprazole Levofloxacin Based Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Controlled Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Ramathibodi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
New drug regimen for Helicobacter pylori eradication, the investigators compare once daily dose dexlansoprazole levofloxacin based quadruple therapy and twice daily dose dexlansoprazole levofloxacin quadruple therapy for helicobacter pylori eradication.
Detailed description
Once daily dose dexlansoprazole should be non inferior to twice daily dose in the eradication of Helicobacter pylori infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexlansoprazole 60 mg once daily | Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2017-03-22
- Last updated
- 2018-04-03
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03087162. Inclusion in this directory is not an endorsement.